HeartFlow – a leader in precision heart care – announced it has closed $215 million in Series F funding led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.
This funding round follows a period of remarkable growth for HeartFlow. And coronary computed tomography angiography (CCTA) and FFRCT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow’s FFRCT technology is covered by 100% of Medicare and over 98% of commercial payers. With the recent FDA clearance of new products, HeartFlow is known as the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology(HeartFlow FFRCT), and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient’s CAD and are the most comprehensive approach to predicting the risk of a heart attack.
What the funding will be used for: This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease(CAD) and guide their treatment decisions.
KEY QUOTES:
“HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology, and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date. The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team, and the opportunity in front of us. We appreciate the support of our investors, both existing and new, who share HeartFlow’s vision to build a new standard of care for people at risk of heart disease.”
— John Farquhar, Chief Executive Officer of HeartFlow
“HeartFlow is a leader in precision heart care and its AI-enabled products promise to help physicians more effectively diagnose and treat heart disease, which continues to be the leading cause of death in the U.S.. We look forward to supporting the company’s commitment to improving cardiovascular care for patients as it heads into this exciting next chapter of growth.”
— Nicholas Downing, M.D., a Managing Director at Bain Capital Life Sciences
